Form 8-K - Current report:
SEC Accession No. 0001493152-24-037958
Filing Date
2024-09-24
Accepted
2024-09-24 16:22:18
Documents
16
Period of Report
2024-09-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39695
2 ex10-1.htm EX-10.1 95864
3 ex10-1_001.jpg GRAPHIC 11054
4 ex99-1.htm EX-99.1 22094
  Complete submission text file 0001493152-24-037958.txt   373091

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE kapa-20240920.xsd EX-101.SCH 3027
6 XBRL LABEL FILE kapa-20240920_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE kapa-20240920_pre.xml EX-101.PRE 24173
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3798
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 241320430
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)